FDA biosimilar approvals set for record-breaking year amid US pricing reforms
The FDA approved 19 biosimilars last year, a sharp jump from the five greenlit by the agency in 2023. GlobalData's Bio/Pharmaceutical Outsourcing Report notes that momentum for biosimilars is set to accelerate.
A total of 18 biologics will lose patent protection in 2025, up from 14 in 2024. This includes blockbuster products such as Amgen's Prolia (denosumab) and Roche's Perjeta (pertuzumab).
GlobalData, the parent company of Pharmaceutical Technology, states that projections indicate that 2025 could surpass 2024's milestone trend.
Debutants in 2024 included Amgen's Wezlana (ustekinumab-auub), the first of six biosimilars to Johnson & Johnson's (J&J's) blockbuster autoimmune drug Stelara (ustekinumab). Stelara generated $10.9bn in 2023, making it one of the top-selling drugs to gain biosimilar competition last year.
There were also five new drugs referencing the ophthalmology drug Eylea (aflibercept) that gained FDA approval in 2024. Regeneron's Eylea saw sales of $5.89bn in sales in 2023 before rivals entered the market.
It was also a strong 2024 for drugmakers in the space. Sandoz reported that biosimilar sales grew 30%, contributing to the company's $10.4bn net sales. Samsung Bioepis, another biosimilar specialist, posted a record-breaking financial year in 2024, with sales and operating profit up by 51% and 112%, respectively.
The spike in approvals is set against a backdrop of governmental pushes to increase reference drug use. US President Donald Trump signed an executive order (EO) earlier this week that overhauled pharmaceutical pricing in the country. According to a Reuters article, pharma companies launched new US drugs at prices 35% higher in 2023, compared to those launched in 2022. Biosimilars and generics can be as much as 80% cheaper than branded alternatives.
Kathryn Kinch, senior pharma product manager at GlobalData, said: 'Increased approvals of biosimilars are likely to lower biologic prices, enhancing consumer demand and competition among drug companies, which will benefit contract manufacturing organisations through higher biosimilar volumes.'
As per a White House fact sheet, the EO 'increases the availability of generics and biosimilars'. Trump already pushed the FDA to expedite the development of lower-cost generic medicines and biosimilars in his first term as president.
Juliana Reed, executive director of the Biosimilars Forum, said: '[We are] pleased to see the Trump Administration announce meaningful action on several fronts, including reforms to make biosimilars available quickly and efficiently to all Americans who need them. The EO also accelerates approval of biosimilars through the FDA and requires transparency and fairness from middlemen who prioritise profits over patients.
'Safe, effective, and lower-cost biosimilars are the clear answer to America's skyrocketing prescription drug costs.'
"FDA biosimilar approvals set for record-breaking year amid US pricing reforms" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Oil markets seen bearish after Trump-Putin Alaska meeting
By Seher Dareen LONDON (Reuters) -Oil markets are set for a muted price reaction when they open on Sunday after U.S. President Donald Trump's and Russian leader Vladimir Putin's meeting in Alaska, at which Trump said a fully-fledged peace deal was the aim for Ukraine rather than a ceasefire. Trump said he had agreed with Putin that negotiators should go straight to a peace settlement - not via a ceasefire, as Ukraine and European allies, until now with U.S. support, have been demanding. Trump said he would hold off imposing tariffs on countries such as China for buying Russian oil following his talks with Putin. He has previously threatened sanctions on Moscow and secondary sanctions on countries such as China and India that buy Russian oil if no moves are made to end the Ukraine war. "This will mean Russian oil will continue to flow undisturbed and this should be bearish for oil prices," said ICIS analyst Ajay Parmar. "It is worth noting that we think the impact of this will be minimal though and prices will likely see only a small dip in the very near term as a result of this news." The oil market will wait for developments from a meeting in Washington on Monday between Trump and Ukrainian President Volodymyr Zelenskiy. European leaders have also been invited to the meeting, a source familiar with the matter told Reuters. "Market participants will track comments from European leaders but for now Russian supply disruption risks will remain contained," said Giovanni Staunovo, analyst at UBS. Brent settled at $65.85 a barrel on Friday, and U.S. West Texas Intermediate at $62.80 - both down nearly $1 before the talks in Alaska. Traders are waiting for a deal, so until that emerges, crude prices are likely to be stuck in a narrow range, said Phil Flynn, a senior analyst with Price Futures Group. "What we do know is that the threat of immediate sanctions on Russia, or secondary sanctions on other countries is put on hold for now, which would be bearish," he said. After the imposition of Western sanctions, including a seaborne oil embargo and price caps on Russian oil, Russia has redirected flows to China and India.
Newsweek
21 minutes ago
- Newsweek
Map Shows Tax Cuts Promised by Trump Administration Across 50 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Tax Foundation, a nonpartisan Washington-based think tank, has produced a map forecasting the effects of President Donald Trump's One Big Beautiful Bill Act on taxes across the United States, broken down to the county level. The White House's website reposted the map, noting that the Tax Foundation said Trump's package would "reduce federal taxes on average for individual taxpayers in every state" and create almost 1 million jobs. Newsweek contacted the Tax Foundation for comment on Saturday outside regular office hours. Why It Matters Trump signed his One Big Beautiful Bill, the centerpiece of his economic agenda, into law on July 4 after it narrowly passed both the House and Senate. The Congressional Budget Office has said the legislation will add $2.4 trillion to the U.S. national debt, a forecast that contributed to a falling out between Trump and his previous close confidant Elon Musk. The One Big Beautiful Bill included sweeping tax cuts, reduced spending on Medicaid, and additional funding for the military and border security. It also raised the U.S. debt ceiling by $5 trillion. What To Know On Wednesday, the Tax Foundation published a study forecasting the effects of the One Big Beautiful Bill on taxes paid by the average American on a county-by-county basis between 2026 and 2035. This was accompanied by a map showing the breakdown by county over this period. Two days later, the White House published a news release welcoming the study, which included a screenshot of the Tax Foundation's map taken for 2026. According to the Tax Foundation, the average tax cut per American for 2026 will be $3,752 because of Trump's spending package. This is forecast to fall to $2,505 in 2030 as some measures expire before increasing again to $3,301 in 2035. A map produced by the Tax Foundation showing the effects of President Donald Trump's One Big Beautiful Bill in 2026 on a county-by-county basis. A map produced by the Tax Foundation showing the effects of President Donald Trump's One Big Beautiful Bill in 2026 on a county-by-county basis. Tax Foundation The states forecast to see the largest tax cuts in 2926 are Wyoming ($5,375), Washington ($5,372) and Massachusetts ($5,139). By contrast, the smallest cuts are expected in West Virginia and Mississippi—at $2,503 and $2,401, respectively. In its report, the Tax Foundation described the One Big Beautiful Bill as "the most significant legislative changes to federal tax policy since the 2017 Tax Cuts and Jobs Act," which was passed in Trump's first term. The president's One Big Beautiful Bill contained a number of tax cuts, including extending corporation and income taxes he imposed in the Tax Cuts and Jobs Act. It also raises the cap on state and local tax deductions over the next five years to $40,000 for those making less than $500,000 per year, reduces tax on tips and overtime pay, and phases out some of former President Joe Biden's energy tax credits. The Tax Foundation also projected that the One Big Beautiful Bill would produce about 938,000 jobs "over the long run," including 132,000 in California and 81,000 in Texas. What People Are Saying White House deputy press secretary Anna Kelly said in the news release: "President Trump's One Big Beautiful Bill is the largest, most consequential tax cut on the middle class ever. Now, the Tax Foundation—the leading nonpartisan tax policy nonprofit—confirms that. Between lower inflation, massive investments, and historic tax cuts, all Americans are reaping the benefits of the Trump Economy—and the Golden Age has just begun." What Happens Next While supporters of Trump's One Big Beautiful Bill may be buoyed by the Tax Foundation's report, which suggests it will result in widespread tax reductions and job creation, critics are likely to continue raising concerns about its effects on the national debt and Medicaid cuts.
Yahoo
44 minutes ago
- Yahoo
Businesses in Colchester and Tendring told to improve after poor hygiene ratings
HYGIENE is important to the success of any company that deals with food. Over the last couple of months, there are five businesses in Colchester and Tendring which have received poor ratings after being inspected by the Food Standards Agency (FDA). The FDA inspects a business and then gives it a rating between zero and five, with the latter being the best. The ratings are given on the business's hygiene and safety, structural compliance and confidence in management. The ratings are routinely updated and can change after each inspection. At of time of writing, these are the businesses that have scored the lowest ratings between May to July. Happy House in Colchester Road, St Osyth Rating: two – Improvement necessary Last inspection date: May 16 The British Grenadier in Military Road, Colchester Rating: one – Major improvement necessary Last inspection date: May 22 Golden Wok Chinese Takeaway in Tower Street, Brightlingsea Rating: two – Improvement necessary Last inspection date: June 13 Royal Gurkha lounge in Magdalen Street, Colchester Rating: two – Improvement necessary Last inspection date: June 18 Bodrum Grill in Crouch Street, Colchester Rating: zero – Urgent improvement necessary Last inspection date: July 3
